Industry Reps Cite Pitfalls In FDA’s New Approach To Postapproval Studies
This article was originally published in The Gray Sheet
Executive Summary
The recent shift of responsibility for device condition-of-approval studies to the FDA's Office of Surveillance & Biometrics could result in more elaborate and burdensome study requirements if device firms are not careful, speakers warned at this year's Regulatory Affairs Professionals Society annual meeting